Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

NCT02672917 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

118

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Pancreatic Cancer

Interventions

DRUG: MVT-5873
DRUG: modified FOLFIRINOX (mFOLFIRINOX)
DRUG: gemcitabine + nab-paclitaxel

Sponsor

BioNTech Research & Development, Inc.